Xifaxan Ibsd denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Xifaxan (rifaximin) for IBS-D as Non-Formulary

A non-formulary denial means UnitedHealthcare's drug formulary for your specific plan does not include Xifaxan (rifaximin) at a covered tier — or places it at a tier requiring additional approval. This is a coverage-design decision, not a clinical judgment about whether the drug is appropriate for you. However, most plans are required to offer an exceptions process, and IBS-D is an FDA-approved indication for Xifaxan, which strengthens a formulary-exception request considerably.

## Your Appeal Rights

• Formulary exception / internal appeal: Under ERISA §503 and ACA requirements, plans must have a process for formulary exceptions when no covered alternative is clinically appropriate. Request a formulary exception in writing, citing medical necessity.
• External review: If the formulary exception and internal appeal are denied, ACA §2719 guarantees independent external review. File within the four-month window from the final internal denial.
• Expedited review: Available when standard timelines would jeopardize health or your ability to regain maximum function.

## Documentation to Gather

1. Diagnosis confirmation — chart documentation establishing the IBS-D diagnosis. 2. Formulary-alternative trials — for each formulary-covered drug in the same therapeutic category, document whether it was tried, for how long, and the outcome. If an alternative was not tried because it is clinically inappropriate for this patient, the prescriber must explain why in writing. 3. Clinical necessity letter — the prescriber should state why Xifaxan specifically is required and why formulary alternatives are not clinically equivalent or appropriate for this patient. 4. FDA label — attach the current prescribing information confirming IBS-D as an approved indication. 5. UHC exception criteria — download UHC's formulary-exception criteria and address each requirement point by point.

## Criteria-Mapping Structure

Reproducing the insurer's own exception criteria alongside your documentation is the most persuasive structure for a formulary-exception appeal:

| UHC Exception Requirement | Patient-Specific Response | |---|---| | Drug has an FDA-approved indication for the condition | Attach FDA label, IBS-D indication highlighted | | Formulary alternative(s) tried and failed or are contraindicated | Dated trial history per chart/pharmacy records | | Clinical need documented by treating prescriber | Attached prescriber letter, dated |

Request UHC's complete formulary-exception policy in writing before you file so your submission addresses every listed criterion.